Paliperidone Extended-Release Injection Regimen for Adherence Gaps
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with psychiatric disorders face challenges with adherence to monthly or quarterly paliperidone palmitate injections, leading to relapse and metabolic side effects, particularly due to the variability in dosing intervals and potential gaps in medication, which can worsen psychiatric comorbidities and increase cardiovascular risk factors.
Innovation Solution
Transitioning patients from monthly or quarterly paliperidone palmitate injections to a six-month dosing interval using a paliperidone palmitate extended-release injectable suspension, allowing for a dosing window of up to 2-3 weeks earlier or later than the scheduled date and providing re-initiation regimens for missed doses, while mitigating adverse blood lipid changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If patients receive monthly or quarterly paliperidone palmitate injections, then symptom control is maintained, but adherence problems and relapse risk increase due to frequent dosing requirements
Solution Approach 1:
The patent implements extended-release formulations that convert frequent monthly/quarterly dosing into less frequent semi-annual or annual injections. This periodic action principle maintains therapeutic plasma concentrations over extended intervals (6-12 months) while reducing the dosing frequency burden on patients, thereby improving adherence without compromising symptom control stability
Solution Approach 2:
The patent employs loading dose regimens administered before the extended-release formulation to pre-establish therapeutic plasma concentrations. This preliminary action ensures that when the extended-release injection is administered, the patient already has adequate drug levels, preventing relapse during the transition period and maintaining symptom control throughout the extended dosing interval
2Ease of operation
If dosing intervals are extended to reduce injection frequency, then adherence improves, but gaps in medication coverage may increase relapse risk
Solution Approach 1:
The patent administers loading doses (e.g., 156 mg or 234 mg) one month before the extended-release injection to pre-establish therapeutic plasma concentrations. This preliminary action ensures continuous symptom control during the extended interval, eliminating gaps that would otherwise occur with longer dosing periods
Solution Approach 2:
The patent combines loading doses with extended-release formulations to maintain continuous therapeutic plasma concentrations over 6-12 months. This continuity of useful action ensures uninterrupted symptom control while allowing extended dosing intervals, thus improving adherence without creating relapse risks from medication gaps
3Reliability
If frequent dosing is maintained to ensure continuous therapeutic effect, then relapse prevention is optimized, but metabolic side effects and cardiovascular risk factors worsen
Solution Approach 1:
The patent extends the dosing period from monthly/quarterly to semi-annual or annual injections, reducing the number of injection events by 80-90%. This periodic action maintains continuous therapeutic coverage through extended-release mechanisms while minimizing the frequency of interventions that trigger metabolic side effects and cardiovascular risk
Solution Approach 2:
The patent maintains continuous therapeutic plasma concentrations over extended periods through extended-release formulations, eliminating the need for frequent dosing events. This continuity achieves relapse prevention while reducing the cumulative metabolic burden associated with repeated injections and frequent clinic visits
4Ease of operation
If extended-release formulations with longer dosing intervals are used, then dosing flexibility and patient convenience improve, but maintaining therapeutic plasma concentrations becomes more challenging
Solution Approach 1:
The patent uses loading doses administered one month before the extended-release injection to pre-establish predictable therapeutic plasma concentrations. This preliminary action creates a known starting point that compensates for the extended release period, ensuring concentrations remain within therapeutic ranges throughout the 6-12 month interval
Solution Approach 2:
The patent employs sophisticated extended-release formulation technologies that precisely control drug release kinetics over extended periods. These formulations use controlled-release mechanisms (osmotic pumps, matrix systems, or depot injections) to maintain stable plasma concentrations despite the long dosing interval, achieving both flexibility and concentration control
Data Source
AI summary
The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formulations. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).